FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
December 20, 2020
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE: EKG) ("CardioComm" or the "Company"), a leading global medical provider of consumer heart monitoring and electrocardiogram ("ECG") acquisition and management software solutions, confirms the start of an out-of-office ECG monitoring program using the HeartCheck™ CardiBeat Handheld ECG monitor, the GEMS™ Mobile RPM Smartphone app and the SMART Monitoring ECG triaging service to support prescribed in-home arrhythmia monitoring.
The Heart Health Institute (“HHI”), a large arrhythmia practice network located in the Greater Toronto Area
(Ontario, Canada), will be recommending the HeartCheck™ CardiBeat to their cardiac patients for up to six
months of in-home, arrhythmia self-monitoring use with an emphasis on detecting a recurrence of atrial
fibrillation and supraventricular tachycardia.
CardioComm’s GEMS™ Mobile Smartphone app supports physician and research-based remote patient
monitoring (“RPM”) requirements including providing rapid ECG reporting directly to the prescribing
physician’s electronic medical records as patient triggered ECGs are taken. ECGs recorded by HHI patients
using the GEMS™ Mobile RPM Smartphone app and the HeartCheck™ CardiBeat be rapidly triaged by
CardioComm’s SMART Monitoring ECG service to detect for the presence of any number of arrhythmias. Any
submitted ECG recordings that show a presence of a cardiac arrhythmia will be flagged so that HHI patients
may be contacted and a follow-up visit scheduled. ECG reports generated through GEMS™ Mobile are eligible
for medical service reimbursement in both Canada and the US.
Physicians at HHI intend to introduce the use of the HeartCheck™ ECG/arrhythmia monitoring technology to
patients with difficult to capture arrhythmias and to reduce clinical workload in dealing with COVID-19
precautions. Due to COVID-19, patients are reluctant to visit their physician for cardiac testing and some
pratices have also implemented new protocols that have made it more challenging to see their patients.
Under the GEMS™ Mobile RPM model, patients will be able to purchase the HeartCheck™ CardiBeat directly
through the HHI offices or on-line directly from CardioComm with an HHI physician referral. ECG reporting will
be made available at no cost to the patients over a six month monitoring period or until a diagnosis has been
made. Following completion of the HHI monitoring period, patients will be able to continue to use the wireless
HeartCheck™ CardiBeat ECG device and GEMS™ Mobile app under the Company’s consumer use model.
The GEMS™ Mobile RPM app is available in Android and Apple Smartphone compatible versions as a free
downloadable app and allows users to generate ECG reports to show to their physician. The app also allows
users to request their ECG to be reviewed by CardioComm’s SMART Monitoring ECG reading service where
the user does not have direct connectivity to their treating physician.
To learn more about CardioComm's products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company's websites at
www.cardiocommsolutions.com and www.theheartcheck.com.
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.